H2 antagonists showed no clear difference in leaving the study early: for any reason compared with placebo (low certainty).
Monoamine modulators showed no clear difference in leaving the study early: for any reason compared with placebo (low certainty).
Topiramate showed no clear difference in leaving the study early: for any reason compared with placebo or no treatment (low certainty).
It is very uncertain whether metformin changes leaving the study early: for any reason compared with placebo or no treatment (very low certainty).
It is very uncertain whether humour‐based interventions changes leaving the study early for any reason compared with standard care (very low certainty).
It is very uncertain whether GROUP PSYCHOSOCIAL THERAPY (GPT) + TAU changes leaving the study early: For any reason compared with TAU (all short‐term) (very low certainty).
STRUCTURAL GROUP THERAPY (SGT) + TAU showed no clear difference in leaving the study early: For any reason compared with HANDICRAFT GROUP (HC) + TAU (all short‐term) (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether COMPUTER‐ASSISTED COGNITIVE REMEDIATION PROGRAMME (CACR) changes leaving the study early: For any reason compared with COMPUTER GAMES (CG, all short‐term) (very low certainty).
PSYCHOEDUCATIONAL (PE) + MULTIFAMILY TREATMENT (MFT) showed no clear difference in leaving the study early: For any reason compared with NONSTRUCTURED GROUP THERAPY (NSGT, all long‐term) (low certainty).
It is very uncertain whether COGNITIVE REMEDIATION THERAPY (CRG) + TREATMENT‐AS‐USUAL (TAU) changes leaving the study early: For any reason compared with TAU (all short‐term) (very low certainty).
Modafinil showed no clear difference in leaving the study early ‐ for any reason compared with placebo (moderate certainty).
It is very uncertain whether chlorpromazine changes leaving the study early ‐ for any reason compared with piperacetazine (very low certainty).
Mirtazapine adjunct showed no clear difference in leaving the study early for any reason compared with placebo adjunct (moderate certainty).
It is very uncertain whether chlorpromazine changes leaving the study early: for any reason compared with clotiapine (very low certainty).
RISPERIDONE DEPOT may leads to higher leaving the study early for any reason ‐ long term compared with TYPICAL DEPOT ANTIPSYCHOTICS (low certainty).
It is very uncertain whether aspirin plus antipsychotics changes leaving the study early: short‐term – for any reason compared with placebo plus antipsychotics (very low certainty).